Knowledge Distillery

No standard therapy, including anticoagulation regimens, is currently recommended for coronavirus disease 2019.

COVID-19 has disproportionately affected minority ethnic populations in the UK. The aim of this study was to quantify ethnic differences in SARS-CoV-2…

Early in the pandemic it was suggested that pre-existing use of non-steroidal anti-inflammatory drugs (NSAIDs) could lead to increased disease…

Individuals admitted to hospital for COVID-19 might have persisting symptoms (so-called long COVID) and delayed complications after discharge.

Following the emergency use authorisation of the Pfizer–BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in…

The consequences of COVID-19 in those who recover from acute infection requiring hospitalisation have yet to be clearly defined.

The aim of this multicentre, European, cohort study involving 34 stroke centres in France, Italy, Spain, and Belgium, was to study early outcomes…

Narcolepsy type 1 (NT1) is a chronic rare hypersomnia of central origin requiring a combination of behavioural and pharmacological treatments. During…

In this paper, recently published in the Journal of Neurology, Neurosurgery and Psychiatry, the authors report initial findings of an ongoing…

In this longitudinal study, recently published in the European Journal of Neurology, the authors sought to describe the neurological manifestations of…

On 21 February 2020, a resident of the municipality of Vo’, a small town near Padua (Italy), died of pneumonia due to severe acute respiratory…

Little is known about the nature and durability of the humoral immune response to infection with SARS-CoV-2.